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Background: Current tools for analgesia are often only partially successful, thus investigations of new targets for
pain therapy stimulate great interest. Consequent to peripheral nerve injury, c-Jun N-terminal kinase (JNK) activity in
cells of the dorsal root ganglia (DRGs) and spinal cord is involved in triggering neuropathic pain. However, the
relative contribution of distinct JNK isoforms is unclear. Using knockout mice for single isoforms, and blockade of
JNK activity by a peptide inhibitor, we have used behavioral tests to analyze the contribution of JNK in the
development of neuropathic pain after unilateral sciatic nerve transection. In addition, immunohistochemical
labelling for the growth associated protein (GAP)-43 and Calcitonin Gene Related Peptide (CGRP) in DRGs was used
to relate injury related compensatory growth to altered sensory function.
Results: Peripheral nerve injury produced pain–related behavior on the ipsilateral hindpaw, accompanied by an
increase in the percentage of GAP43-immunoreactive (IR) neurons and a decrease in the percentage of CGRP-IR
neurons in the lumbar DRGs. The JNK inhibitor, D-JNKI-1, successfully modulated the effects of the sciatic nerve
transection. The onset of neuropathic pain was not prevented by the deletion of a single JNK isoform, leading us to
conclude that all JNK isoforms collectively contribute to maintain neuropathy. Autotomy behavior, typically induced
by sciatic nerve axotomy, was absent in both the JNK1 and JNK3 knockout mice.
Conclusions: JNK signaling plays an important role in regulating pain threshold: the inhibition of all of the JNK
isoforms prevents the onset of neuropathic pain, while the deletion of a single splice JNK isoform mitigates
established sensory abnormalities. JNK inactivation also has an effect on axonal sprouting following peripheral
nerve injury.
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Neuropathic pain refers to a variety of chronic pain con-
ditions that are mediated via different pathophysiological
mechanisms [1]. Our incomplete understanding of its
pathogenesis has hampered the development of effective
treatments for this terribly disabling disease. Since sen-
sory neurons connect peripheral tissues with the central* Correspondence: giusi.manassero@unito.it
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distribution, and reproduction in any mediumnervous system, they play a key role in the reception of
peripheral information, and in its rapid transduction and
integration [2]. Transection of peripheral axons of pri-
mary sensory neurons, an established model for the
study of neuropathic pain, results in profound alterations
in sensory neuron metabolism, in their survival and re-
generative potential, excitability, transmitter function,
and in their sensitivity to diverse extrinsic and intrinsic
signals [3]. When axons are sectioned, sensory neurons
undergo long- lasting plastic changes in their neuro-
chemical and electrical properties [4], which can result
in neuropathic pain, placing a disabling burden on the
affected individual [2,5].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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Ca++ and Na+, which elicits electrical responses that
back-propagate to the cell body in the dorsal root gan-
glion (DRG) and contribute to the activation of several
protein kinase pathways, including protein kinase (PK)
A, PKC, and mitogen-activated protein kinases (MAPKs)
[5,6].The MAPK family comprises three major members:
extracellular signal-regulated kinase (ERK), p38, and
c-Jun N-terminal kinase (JNK), all of which are impli-
cated in the nociceptor sensitization that is associated
with inflammation and peripheral neuropathy [7-9].
An increasing body of evidence suggests that the JNK
cascade is a critical signaling pathway for the onset and
the maintenance of neuropathic pain, via distinct
mechanisms in the cells of the DRGs and spinal cord:
following nerve injury, JNK is rapidly activated by phos-
phorylation, and JNK expression remains elevated for
weeks, until the neuron dies or until its axon regenerates
[9-11]. Recently, a cell- penetrating and proteinase-
resistant peptide inhibitor of the JNK binding domain of
JNK-interacting protein-1 (D-JNKI-1) was developed,
with the goal of competitively inhibiting the binding
of JNK to its substrates [12-14]. D-JNKI-1 effectively
blocks the onset of mechanical allodynia, a characteristic
behavioral response for neuropathic pain [9,15]. How-
ever, D-JNKI-1 treatment did not permanently prevent
neuropathic pain: allodynia re-appeared when the drug
was discontinued [9].
The JNK protein kinase in mammals is encoded via
three genes: Jnk 1 and Jnk 2 are ubiquitously expressed,
while Jnk 3 is expressed primarily in the nervous system,
endocrine pancreas, heart, and testicles [16,17]. The JNK
isoforms differ from each other in the affinity of their
binding with the Activating Transcription Factor (ATF) 2,
with EtsLiKe gene (Elk)-1, and with c-Jun transcription
factors. Individual JNKs may thus selectively target specific
transcription factors in vivo [18]. However, the relative
contribution of each JNK isoform to the onset and main-
tenance of neuropathic pain remains to be identified.
In this study, we use unilateral sciatic nerve transec-
tion (SNT) in knockout (KO) mouse models of neu-
ropathic pain, in combination with JNK inhibition with
D-JNKI-1, to analyze the contribution of individual
JNK isoforms to the animal’s physiology and behavior.
We show that following SNT, activated JNK induces the
up-regulation and phosphorylation of the transcription
factor c-Jun in the nucleus of DRG neurons, leading to
the formation of an Activator Protein (AP)-1 complex
that induces a number of downstream genes [10,19]. We
further show that this neuronal response to injury com-
prises a set of changes that are primarily aimed at restor-
ing disrupted connections and recovering function. In
spite of the clear, adaptive nature of this response, some of
its outcomes, such as abnormal sensitivity to peripheralstimuli [20], are clearly maladaptive; this led us to examine
also the expression of growth associated protein (GAP)-43
and Calcitonin Gene Related Peptide (CGRP) in the
DRGs, as indicators of injury-induced molecular changes
[20,21] that could be related to the alterations in sensory
function. Indeed, a relationship among the JNK pathway
and GAP-43 [10,22] and CGRP [23] expression has been
reported.
Results
Basal expression of JNK isoforms in the adult mouse
DRGs
Several studies have reported on JNK pathway activation
in DRG neurons [9,10,22], but data on the basal mRNA
expression of JNK isoforms in adult mouse DRGs are
lacking. We first evaluated this basal expression in adult
wild-type (wt) mice by qualitative RT-PCR (Figure 1A),
then used western blotting to determine basal expression
of phosphorylated (p) and total JNK proteins in adult wt
DRGs: pJNK was present as a stronger (46 kDa) and a
weaker (54 kDa) isoform, whilst total JNK was present
as a weaker (46 kDa) and a stronger (54 kDa) isoform
(Figure 1B). pJNK increases after STN (p46 0.80 + 0.11,
p< 0.05; p54 0.88+ 0.12, p< 0.01, one-way ANOVA vs
wt contralateral side) (Figure 1B-C). The increase in the
pJNK/JNK ratio is mostly due to changes in p54 iso-
form (p54/54 0.75 + 0.10, one-way ANOVA, p< 0.01 vs
wt contralateral side; p< 0.05 vs wt unoperated mice)
(Figure 1D).
D-JNKI-1 treatment
Preliminary experiments on intact wt animals that
were systemically treated with the JNK peptide inhibitor
D-JNKI-1, or with vehicle (saline), did not show any sig-
nificant difference in GAP43 and CGRP-immunoreactivity
(IR) in DRGs, nor did they show alteration in pain sensi-
tivity between the two groups of mice (data not shown).
Thus the D-JNKI-1 treated mice and the KO groups were
compared to the same group of wt mice group, in order
to minimize the number of animals used.
Increase of GAP43-IR in wt DRG neurons is prevented by
JNK blockade
GAP43 is an axonal protein that is developmentally
regulated, and is reactivated in some adult neurons fol-
lowing injury [25-26]. We evaluated GAP43 expression
in L4 DRGs 72h post-surgery. In unoperated mice, an
average of 11.03%+ 3.37 neurons in L4 DRGs of both
sides display some faint immunohistochemical labelling
(Figure 2A, 2B). At 72h, GAP43-IR was increased ipsilat-
eral to the SNT, compared to the unoperated group
(25.11%+ 1.40, t-test, p< 0.01) (Figure 2A, 2C): the
contralateral DRG showed no change (12.73%+ 1.07)
(Figure 3).
Figure 1 Basal expression of JNK in the adult mouse DRGs. (A) m-RNA expression of Jnk1, Jnk2 and Jnk3 in lumbar mouse DRGs, analyzed
by RT-PCR. β-actin mRNA expression was used as the internal standard. (B) Western blot analysis of pJNK and JNK in the L3-L6 DRGs from SNT
(ipsilateral and contralateral) and unoperated wt mice. (C-D) Densitometric analysis of pJNK (C) and pJNK/JNK ratio (D) p46 (white bars) and p54
(black bars) isoforms in SNT (ipsi: ipsilateral; contra: contralateral) and unoperated (unop) wt mice. Experiments were repeated three times. Data
represent means + SEM (n = 24 from three independent experiments). *, # p< 0.05; ## p< 0.01 by one-way ANOVA.
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activation in DRG neurons [9], and since it has been
proposed that c-Jun regulates the expression of growth-
associated genes [10,22], we asked whether blockade of
the JNK pathway affects injury-induced GAP43 activa-
tion. D-JNKI-1 treatment significantly reduced the num-
ber of GAP43- immunoreactive neurons (18.54%+ 1.66
on the operated side, t-test, p< 0.05 vs wt) (Figure 2A,
2E), whereas D-JNKI-1 had no effect on baseline levels
of GAP43 (11.3%+ 2.71 on the control side, p = 0.82 vs
unoperated mice) (Figure 2A, 2D).
GAP43-IR in DRG neurons of specific JNK KO mice
following STN
The number of GAP43-IR neurons in L4 DRGs of unop-
erated mice that had the genes for the different JNK iso-
forms deleted was similar to that of unoperated wt
animals (JNK1 KO 12.38%+ 4.32; JNK2 KO
11.61%+ 1.97; JNK3 KO 11.24%+ 2.75, one-way
ANOVA, p = 0.99) (Figure 3A). At 72h post-transection,
GAP43-IR was unchanged in both JNK1 and JNK3 KO
mice (JNK1 KO: 12.66%+ 0.26, p = 0.57 vs JNK1 KO
unoperated mice; JNK3 KO: 18.83%+ 1.95, p = 0.28 vs
JNK3 KO unoperated mice) (Figure 3B, 3D). On con-
trast, immunoreactivity in JNK2 KO mice was similar to
that of the operated wt animals (23.69%+ 3.21, t-test p
< 0.05 vs JNK2 KO unoperated mice) (Figure 3C).
CGRP-IR downregulation in wt DRG neurons is prevented
by JNK blockade
CGRP is constitutively expressed in L4 primary sensory
neurons (22.83%+ 2.45) (Figure 4A, 4B), and is mainly
localized in small- and medium-sized cells, as well as in
some large neurons. Scattered sensory fibers in theseDRGs are also immunolabeled. Since axotomy induces a
time-dependent decrease in CGRP-IR in primary sensory
neurons [23], we assessed CGRP-IR 72h post-lesion.
CGRP-IR was decreased ipsilateral to the SNT, com-
pared to the unoperated mice and also compared to the
contralateral side (8.37%+ 1.11, t-test, p< 0.001 vs unop-
erated mice) (Figure 4A, 4C). Pretreatment with D-
JNKI-1 partially reversed the CGRP downregulation
(14.10%+ 1.31, t-test, p< 0.05, vs wt ipsilateral side) (Fig-
ure 4A, 4E). D-JNKI-1 alone had no effect on baseline
levels of CGRP (22.65%+ 1.89, t-test, p = 0.96 vs unoper-
ated mice) (Figure 4A, 4D).
CGRP-IR in DRGs of JNK KO mice following STN
In JNK KO mice, the number of CGRP-IR neurons in L4
DRGs was unchanged relative to the intact wt DRGs
(JNK1 KO 22.27%+1.87; JNK2 KO 22.06%+1.21; JNK3
KO 21.29%+1.03, one-way ANOVA, p= 0.94) (Figure 5A).
Seventy-two hours post-nerve transection, the frequency
of CGRP-IR neurons was markedly decreased in JNK3 KO
mice (11.31%+ 1.54, t-test, p< 0.001 vs JNK3 KO unoper-
ated mice), but not in JNK1 or JNK2 KO mice (JNK1 KO:
20.54%+2.45, t-test, p = 0.81 vs JNK1 KO unoperated
mice; JNK2 KO: 18.17%+1.02, t-test, p = 0.12 vs JNK2 KO
unoperated mice) (Figure 5B-D).
Locomotor activity of unoperated JNK KO mice
To assess pain in terms of motor withdrawal in an ani-
mal model of injury, we first showed that motor func-
tions were intact under basal conditions. Locomotor
activity of mutant and wt mice was tested, by video and
ink walking track analysis (Additional file 1), by rotarod
test and by open field test. Before injury, the toe spread
and the print length average values of both sides in all
Figure 2 GAP43-IR downregulation is partially prevented by JNK blockade in L4 primary sensory neurons of wt mice. (A) The effect of
D-JNKI-1 on SNL-induced GAP43 expression in L4 DRG neurons. The immunoreactivity for GAP43 in DRG neurons was quantitated with the
Neurolucida software, and expressed as a percentage of positive neurons. **p< 0.01 by tTest compared with unoperated wt; n = 8. #p< 0.05 by
tTest compared with SNL ipsi; n = 8. Values are mean+ SEM. (B-E)Representative DRG sections immune-stained for GAP43: (B) unoperated wt
displays faint immunohistochemical labelling; (C) a significant increase in GAP43-IR occurred in DRGs, 72h after nerve injury; (D) D-JNKI-1 alone
has no effect on baseline GAP43 levels; (E) D-JNKI-1 treatment partially prevents GAP43-IR upregulation on the lesioned side. Scale bar = 50 μm.
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ively, whereas the average stride length was 3.52 cm. In
an open field box test, these parameters in JNK KO mice
were undistinguishable from those of wt mice (p = 0.91,
one-way ANOVA) (Additional file 2). Moreover, all mice
were able to remain on the rotating rod for 300 seconds
(n = 12 mice/group). KO littermates for the differentJNK isoforms were undistinguishable from their wt
counterparts in the normal cage environment.
Response to mechanical stimulation is decreased in JNK
KO mice following SNT
The mechanical nociceptive threshold of both hind-
paws, in response to dynamic plantar aesthesiometer
Figure 3 GAP43-IR in L4 primary sensory neurons of JNK KO
mice following STN. Percentage of GAP-43-positive primary sensory
neurons in L4 DRG in wilde type (A), JNK1 (B), JNK2 (C) and JNK3 (D)
KO mice. GAP43 is constitutively expressed in primary sensory
neurons of unoperated mice of each group (white bars).
Seventy-two hours post lesion, GAP43-IR upregulation, which occurs
in wt (A) and JNK2 KO (C) mice is absent both in JNK1 (B) and JNK3
(D) KO mice. #, £, $ p< 0.05, **p< 0.01 by tTest; n = 6 mice/group.
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wt mice from 2 days prior to-SNT to 30 days post-SNT
(Figure 6). Before nerve injury, paw withdrawal thresh-
old to mechanical stimulation was comparable in all
mice, suggesting that sensory transmission is not altered
in the JNK KO mice. The time-course of the paw with-
drawal threshold showed that, within 24 hours after
cutting the sciatic nerve, the mechanical nociceptive
threshold was decreased by 30-40% in all mice ipsilateral
to the lesion, compared to the contralateral side; the foot
withdrawal force was <7 g. We observed a mechanical
hyperalgesia in the denervated hindpaw of the wt mice:
this alteration persisted throughout the 30-day observa-
tion period (Figure 6, open symbols). By 72h, the paw
withdrawal threshold in JNK1, JNK2 and JNK3 KO mice
progressively increased ipsilateral to SNT (Figure 6A-C).
Two-way ANOVA of repeated measures for mechan-
ical hyperalgesia of ipsilateral hindpaws showed a
significant main effect for groups, i.e. all individual
JNK isoforms mutants vs wt (JNK1 KO: F1,19 = 17.444,
p = 0.0005; JNK2 KO: F1,23 = 17.132, p = 0.0004; JNK3
KO: F1,23 = 39.203, p< 0.0001) and time (JNK1 KO:
F15,285 = 8.127, p< 0.0001; JNK2 KO: F15,345 = 10.701,
p< 0.0001; JNK3 KO: F15,345 = 13.938, p< 0.0001), in
absence of significant differences for withdrawal force
of contralateral hindpaws (JNK1 KO: F1,19 = 0.273,
p = 0.6076; JNK2 KO: F1,23 = 2.019; p = 0.1688, JNK3
KO: F1,23 = 0.001; p = 0.9819) throughout the 30-day
observation period. Post-hoc comparisons revealed
significant differences among JNK2 KO vs wt mice
from 24h to day 30, whereas JNK1 and JNK3 KO
mice were significantly different from wt control
from day 5 to day 30 (p< 0.05, Tukey-Kramer). We
performed an additional statistical analysis comparing
the withdrawal force of the ipsilateral with the
contralateral hindpaw of JNK KO vs wt mice. Two-
way ANOVA for repeated measures, followed by
post-hoc comparisons, showed significant main effect
for groups (JNK1 KO: F1,19 = 29.516, p< 0.0001; JNK2
KO: F1,23 = 18.532, p = 0.0003; JNK3 KO: F1,23 = 73.274,
p< 0.0001) and time (JNK1 KO: F15,285 = 3.871, p< 0.0001;
JNK2 KO: F15,345 = 3.439, p< 0.0001; JNK3 KO:
F15,345 = 6.105, p< 0.0001) throughout the 30-day observa-
tion period (p< 0.05, Tukey-Kramer).
Response to mechanical stimulation in wt mice after JNK
blockade
To compare the behavioral effects of knocking out single
JNK isoforms vs those resulting from JNK activity block-
ade, D-JNKI-1 was injected 30 min before SNT into a
separate group of wt mice. Previous reports used differ-
ent protocols of drug administration, such as systemic or
intrathecal injection, to test the effect of D-JNKI-1 pain
sensitization [9,15,27]. Here, we administered D-JNKI-1
Figure 4 CGRP-IR downregulation is prevented by JNK blockade in L4 primary sensory neurons of wt mice. (A) Effect of D-JNKI-1 on
SNT-induced CGRP expression in L4 DRG neurons. CGRP-IR in neurons was quantitated with the Neurolucida software, and expressed as a
percentage of positive neurons. *p< 0.05 and ***p< 0.001 by tTest compared with unoperated wt; n = 11. #p< 0.05 by tTest compared with SNL
ipsi; n = 8. Values are mean+ SEM (B-E). Representative 20X DRG sections immunoistochemically stained for CGRP: (B) baseline expression of
CGRP-IR in the DRGs of the wt mice; (C) a significant decrease in CGRP-IR occurs in injured DRGs after 72h; (D) D-JNKI-1 alone has no effect on
baseline CGRP-IR levels; (E) D-JNKI-1 treatment prevents downregulation of CGRP-IR. Scale bar = 50 μm.
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Figure 5 CGRP-IR following injury in L4 primary sensory
neurons of JNK KO Mice. Percentage of CGRP-positive primary
sensory neurons in L4 DRG in wt (A), JNK1 (B), JNK2 (C) and JNK3
(D) KO mice. CGRP is constitutively expressed in primary sensory
neurons of unoperated mice of each group (white bars).
Seventy-two hours post lesion, CGRP-IR , which is downregulated in
wt (A) and JNK3 KO (D) mice, is unchanged both in JNK1 and JNK2
KO mice (B, C). ** and ##, p< 0.01 and ***p< 0.001 by tTest; n = 6
mice/group.
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triple JNK1/2/3 KO mouse. In a first set of experiments
(Figure 7, closed black symbols), we made repeated
intraperitoneal injections of D-JNKI-1 every fourth day,
starting from 30 min before surgery. The same delivery
of D-JNKI-1 to unoperated animals did not alter basal
pain sensitivity (data not shown). In mice that underwent
SNT, two-way ANOVA of repeated measures for
mechanical hyperalgesia of ipsilateral hindpaws yielded a
significant main effect for multiple D-JNKI-1 injections
(F1,23 = 52.361, p< 0.0001), time (F15,345 = 6.353, p< 0.0001)
and interaction (F15,345 = 3.203, p< 0.0001), in absence of
significant differences for withdrawal force of contralateral
hindpaws (F1,23 = 0.296, p=0.5914) throughout the 30-day
observation period. Post-hoc comparisons showed that
multiple D-JNKI-1 injections attenuated the onset of
mechanical hyperalgesia at 24 h (p< 0.05, Tukey-Kramer).
The anti-hyperalgesic effect of D-JNKI-1 reached a peak on
day 5(p< 0.05, Tukey-Kramer), and remained elevated
until day 12 (p< 0.05, Tukey-Kramer). This beneficial
effect was still detectable,albeit it was reduced, at day 30
post-SNT (p< 0.05, Tukey-Kramer). Comparing the
withdrawal force of the ipsilateral versus contralateral
hindpaw of mice having received multiply D-JNKI-1
injects vs wt untreated mice, two-way ANOVA of
repeated measures, followed by post-hoc comparisons,
uncovered a significant main effect for treatment
(F1,23 = 88.499, p< 0.0001), during the overall time course
(p< 0.05, Tukey-Kramer).
Multiple D-JNKI-1 injections seem to have a cumula-
tive effect on neuropathic pain symptoms [15]: neuro-
pathic pain develops once peptide infusion is terminated
[9]. We thus performed a second set of experiments, in
which mice received only one injection of D-JNKI-1 30
min before surgery (Figure 7, closed grey symbols).
Throughout the 30 days of observation, the latter proto-
col produced an anti- nociceptive effect on mechanical
hyperalgesia similar to that observed following repeat
peptide injections. Accordingly, the single-injection
procedures induced a significant analgesic effect
compared to wt untreated mice, as shown by post-hoc
comparisons (p< 0.05, Tukey-Kramer). The time-course of
the anti-hyperalgesic effect of the second treatment
protocol was less fluctuating than the trend of the multiple
D- JNKI-1 administration, and it was significantly different
from the data obtained from SNT wt mice throughout the
30-day observation period (p< 0.05, Tukey-Kramer). Two-
way ANOVA of repeated measures for mechanical hyper-
algesia of ipsilateral hindpaws showed significant main ef-
fect for single D-JNKI-1 administration (F1,23 = 52.361,
p< 0.0001) time (F15,345 = 6.353, p< 0.0001) and inter-
action (F15,345 = 3.203, p< 0.0001) during the overall time
course. In the second treatment protocol, comparing the
withdrawal force of the ipsilateral with the contralateral
Figure 6 Neuropathic pain behaviour in JNK KO and wt mice. Mechanical hyperalgesia induced by SNT injury in JNK KO compared to wt
mice: percentage ratio between ipsilateral and contralateral withdrawal thresholds in JNK1 KO (●), JNK2 KO (■), JNK3 KO (▲) and wt (○) mice.
Asterisks indicate significant differences in percentage ratio of JNK KO vs wt mice (*p< 0.05; **p< 0.01; ***p< 0.001). n = 8 JNK1 KO, 12 JNK2 KO,
12 JNK3 KO, 13 wt.
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ANOVA of repeated measures, followed by post-
hoc comparisons, showed a significant main effect for
treatment (F1,23 = 122.006, p< 0.0001) and time
(F15,345 = 4.836, p< 0.0001) during the whole time
course (p< 0.05, Tukey-Kramer).Figure 7 Neuropathic pain behavior in wt mice after JNK blockade. M
D-JNKI-1 administration. Percentage ratio between ipsilateral and contralate
single (♦), or multiple (♦) injections, compared to wt (○). n = 12 single andAutotomy behavior
The degree of self-mutilation, i.e. autotomy, of a dener-
vated limb following axotomy is positively correlated to
spontaneous pain [28]; this behavior has been observed
even in humans suffering from neuropathic pain [29].
The time-course for the development of autotomy in allechanical hyperalgesia induced by SNT in wt mice is prevented by
ral withdrawal thresholds in wt mice injected with D-JNKI-1, after
n = 12 multiple injections, n = 13 wt.
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is shown in Figure 8. Autotomy was most frequent in wt
mice treated with a single D-JNKI-1 injection, followed
by JNK2 KO mice and untreated wt mice. In fact, four
days after administration, D-JNKI-1 is not active any
more (our laboratory, unpublished observations). Some
JNK2 KO mice started to hurt their own ipsilateral hind-
paws the day after surgery, whereas in wt mice treated
with a single D-JNKI-1 injection and in untreated wt
mice, the first bites appeared at day 5 and day 8, respect-
ively. Surprisingly, autotomy behavior was completely
absent in both JNK1 and JNK3 KO mice, and in the ani-
mals had received multiple D-JNKI-1 injections.Discussion
Our overarching hypothesis is that the signals resulting
in nociceptor sensitization are not separated, since the
PKA, PKC, and MAPK cascades, once activated, partially
or completely converge to induce hyperalgesia [2]. The
JNK pathway is believed to be a critical signaling path-
way in the processing of neuropathic pain via distinct
mechanisms in the DRGs and spinal cord [9,10,24]. In
this study, we used single JNK knockout mice to analyze
the contribution of individual JNK isoforms to the devel-
opment of neuropathic pain after unilateral SNT. We
also studied the relationship between JNK activity and
the expression of GAP-43 and CGRP, in order to relate
changes at the molecular and cellular levels to the devel-
opment of sensory alterations.
Our findings document, for the first time, that: (1)
JNK is involved in pain–related behavior and in theFigure 8 Autotomy score. Autotomy was scored throughout the 30-day
D-JNKI-1 once (◊), next highest in JNK2 KO mice (■) and then in wt mice (
(■) started to hurt their own ipsilateral hindpaws before wt injected with D
(●) and JNK3 KO (▲), and in animals that received multiple D-JNKI-1 injecti
JNK1 KO, JNK3 KO and multiple D-JNKI-1 vs wt *p< 0.05; **p< 0.01; single
of repeated measures. n = same as in Figures 6 and 7.modulation of GAP43 and CGRP expression in lumbar
DRG neurons following SNT; (2) administration of a
JNK inhibitor partially prevents these effects; (3) the de-
letion of a single specific JNK isoform partially prevents
the maintenance of the sensory alteration, but not the
onset of neuropathic pain symptoms such as mechanical
hyperalgesia; (4) JNK inhibition in wt mice, as well as
deletion of JNK1 or JNK3, abolishes SNT-induced autot-
omy behavior.
The experimental model
Animal models of neuropathic pain are mostly based on
peripheral nerve injury for reproducibility and simplicity
[30]. Axotomy was the first widely used model, since it
simulated the clinical condition of amputation [31].
Complete nerve transection is associated with spontan-
eous pain-related behaviors, allodynia and hyperalgesia,
and with autotomy, or the self-mutilation of the injured
foot. These three behavioral signs are used as indices to
measure the degree of neuropathic pain, and to evaluate
the effects of therapy [30]. In 2008, the International As-
sociation for the Study of Pain (IASP) modified many of
the definitions in the pain field including that: i) the
term allodynia should be used only when the test stimu-
lus, e.g. thermal or mechanical, does not normally acti-
vate nociceptors; ii) when this is not clearly the case,
“hyperalgesia” is the preferred term [32]. For this reason,
in this study we analyzed the onset and maintenance
of neuropathic pain in terms of mechanical hyperal-
gesia, since we tested the animal’s behavior by means
of anautomated Von Frey test, which uses mechan-
ical stimulation.observation period. Autotomy is highest in wt mice injected with
○). Whilst regard to the time-course for onset of autotomy, JNK2 KOs
-JNKI-1 once (◊) and in wt(○). This behavior was absent in both JNK1
ons(♦). Autotomy scores are presented as mean+ SEM.Significance:
D-JNKI-1 vs wt # p< 0.05; ## p< 0.01; ### p< 0.001, two-way ANOVA
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involved in neuropathic pain
In this study we have focused our attention on the pri-
mary sensory neurons of the lumbar tract, which are the
first neurons involved in pain transmission from the
hind limb periphery. Following peripheral axotomy,
reorganization of central DRG projections to the spinal
cord are thought to mediate neuropathic pain [4]. Earlier
studies proposed different explanations of how neuronal
perikarya can receive information about a distant axon
injury, including via retrograde transport of injury-
induced proteins and/or via decreased target-derived
trophic support [26,33].
It has been shown, both in vitro and in vivo, that axot-
omy of sensory neurons causes a rapid, massive and
transient increase in JNK expression; this is followed
by the activation of c-Jun, which supports axonal out-
growth and neuron survival [34,35]. In fact, JNK blockade
by D-JNKI-1 and SP600125 reduces c-Jun phosphoryl-
ation in DRGs, and hampers axonal outgrowth, both in
terms of the length and number of regenerating axons [35].
Many JNK scaffold proteins interact with kynesin 1,
which is involved in vesicular trafficking within axons
[36]. JNK is activated locally in the axon as part of a
damage signal, which is retrogradely transported in a
molecular assembly called a signalosome [37]. In cul-
tured cortical neurons, JNK-interacting protein (JIP)1
has been shown to be involved in axonal elongation,
since it is localized at the tip of the growing axon, and
co-labels with the axonal marker Tau-1 [38]. Chang
et al. [39] demonstrated that JNK1 KO mice exhibit
progressive degeneration of neurites, associated with
shorter microtubules,reduced Microtubules Associated
Protein (MAP)1B, and MAP2 phosphorylation. MAP1-
B is implicated in axonal regeneration, as seen in DRG
cultures [40] and its phosphorylation is increased in
the rearrangement of axonal circuitry following spinal
cord injury, together with JNK activation [41]. All three
JNK isoforms seem to contribute to neurite re-growth
in PC12 cell culture [42]. The absence of the JNK target
c-Jun impairs the expression of cluster of differentiation
(CD)44, galanin or alpha7beta1 integrins, molecules
known to be involved in regeneration [19].
To assess the correlation between JNK activity and
axonal regeneration, we analysed GAP43-IR in DRGs
after SNT. JNK expression and its activation persist for at
least 30 days after axotomy if regeneration is blocked
[10]; JNK activation in DRG neurons would thus initially
promote survival after injury, and later would operate as
part of a growth program [10]. In agreement with this, we
document here that GAP43 immunoreactivity increases
in axotomized primary sensory DRG neurons, and that
this increase is partially prevented by D-JNKI-1 adminis-
tration, or by deleting the genes for JNK1 and JNK3.In primary somato-sensory neurons, CGRP is localized
in peripheral axons, in their somata in the DRG, and in
unmyelinated and thin myelinated central afferent fibers,
where it has been implicated in the transmission/modu-
lation of pain [43]. The role of GCRP, as well as that of
substance P in neuropathic pain has been poorly investi-
gated, partly because they are depleted after peripheral
nerve lesion [23]. Impaired information-processing in the
spinal cord may play an important role in the develop-
ment of sensory abnormalities that result from peripheral
nerve injury. It is likely that the lesion-induced downre-
gulation of substance P and CGRP attenuates the trans-
mission of peptide-related information at the first
synapse in the dorsal horn; such changes may represent
adaptive responses that limit the consequences of periph-
eral nerve damage to the organism as a whole, and that
promote survival and recovery of individual neurons
[44]. In animal models that investigate pathways that
regulate inflammatory responses, a relationship between
the JNK pathway and CGRP has been documented
[22,23]. In agreement with previous studies [23], we
report here that in axotomized primary sensory DRG
neurons, CGRP activity is down-regulated. Moreover,
our results following D-JNKI-1 treatment further under-
score a relationship between JNK pathway activation and
CGRP expression. We propose that, following nerve
injury, activation of JNK pathway may influence CGRP
regulation, mediated via JNK1 and JNK2 isoforms.
Studies on pain have primarily focused on neurons;
however Zhuang et al. [9] demonstrated that spinal
nerve ligation (SNL) also activates JNK1 in spinal astro-
cytes, and that such activation is essential for the main-
tenance of neuropathic pain. Glial changes, associated
with an increased sprouting of primary nociceptive affer-
ents (C and A-δ fibers) that enter the spinal cord, sug-
gest a strict correlation between neuro-glial plasticity
changes and peripheral sensitization [45,46]; these find-
ings highlight the role of glia in pain transmission and
suggests that JNK could also participate in this mechan-
ism. In support, intratechal administration of TNF-α-
activated astrocytes induces mechanical allodynia, which
is preserved by D-JNKI-1 treatment [47]. Related to this,
the relationship between NGF expression and JNK acti-
vation should be further investigated: on one hand, sev-
eral reports claim that NGF, whose levels are increased
in inflamed tissues, induces the activation of JNK in
DRGs [24]. On the other hand, NGF administration pre-
vents the facilitation of pain transmission at the level of
the superficial laminae of the spinal cord [48].
Role of JNK in pain behavior
Even though studies of knockout mice have some limita-
tions, such as the occurrence of compensatory changes
for the knocked out gene or the dependence of the
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ings exclude the possibility that the deletion of a specific
JNK isoform results in abnormalities of locomotion or
motor coordination, or in the alteration of the mechanical
pain threshold. On the contrary, following SNT, KO mice
displayed a decreased mechanical pain threshold compared
to wild type animals: inhibition of JNK by D-JNKI-1 also
had similar effects. However, JNK inhibition by D-JNKI-1
does not necessarily act as analgesic: since a JNK inhibitor
can dramatically affect the production of cytokines [50],
we suppose that it can function as an anti-hyperalgesic
and/or as a neuromodulator, by restoring the baseline or
normal pain threshold of the injured mice to which it
is administered. Thus D-JNKI-1, instead of diminishing
the stimulus-dependent response, would prevent that
response, either by suppressing the pain-associated suffer-
ing or by directly reducing the responsiveness of nocicep-
tors. D-JNKI-1 could thus be used to prevent and treat
the onset of SNT-induced neuropathic pain.
D-JNKI-1 treated mice exhibit hypoalgesic responses
to neuropathic pain within 30 days post- surgery, sug-
gesting that JNK isoforms play a critical role in pain per-
ception. These findings are consistent with recent
results obtained using intrathecal or systemic delivery of
D-JNKI-1 in another animal model for the study of
neuropathic pain [9,27], in which the authors showed
that JNK blockade prevents the development of neuro-
pathic pain. Even though our work was aimed at investi-
gating the role of JNK in modulating injury-induced
cellular changes of DRGs in relation to concomitant pain
behavior, we are aware of the involvement of supraspinal
centers in the control and in the genesis of neuropathic
pain. In fact, several reports refer changes in the expres-
sion of MAPKs, and namely of JNK, in somatosensory
[51] and cingulate [52] cortex and in the hippocampus
[53,54]. On the contrary, no changes were reported in
the thalamus in a model of chronic pain in rats [55]. Al-
though the parallel changes of DRG markers and pain
behavior that we observed suggest that these phenomena
may be causally related, in our experimental design, both
in transgenic and in D-JNKI-1-treated mice single or all
JNK isoforms were blocked in the entire brain. There-
fore, further studies will be necessary to dissect the spe-
cific contribution of supraspinal centers in neuropathic
pain and the relevant role played by JNK. Similarly, spe-
cific analysis and targeted manipulaitions of JNK expres-
sion or activity would be required to elucidate functional
changes of intra- and supra spinal circuits involved in
the pathogenesis of neuropathic pain.
Autotomy behavior
Autotomy, or self mutilation can be interpreted either as
a response to a persistent irritative stimulus, the failure
to recognize the limb as self, or both. Our strain of mice,C57BL/6, displays a high autotomy score following sci-
atic nerve tight ligature [56]. Whereas JNK2 KO and wt
mice displayed this behavior following SNT, mice with
the JNK1 or JNK3 genes deleted, also mice treated with
D-JNKI-1, displayed no autotomy lesions. This finding
further supports a role for JNK in neuropathic pain.
However, the increase in autotomy lesions which we
observed in operated JNK2 KO mice apparently contra-
dicts this view. Indeed, JNK2 KO mice show both
GAP43 upregulation and the autotomy phenotype,
whereas the other two strains failed to activate GAP43
and did not develop autotomy. Thus, GAP43 upregula-
tion correlates with autotomy, which has been related to
spontaneous pain [28]. This observation was somewhat
surprising, since all JNK isoforms appear to be involved
in the maintenance of neuropathic pain, as assessed by
plantar aesthesiometer stimulation. However, it is likely
that the appearance of autotomy and mechanical hyper-
algesia following noxious plantar stimulation are elicited
by different mechanisms that involve distinct JNK iso-
forms. In fact, autotomy score and Von Frey filament
test (which is comparable to the automated Von Frey
test we used in our study) reflect two different aspects of
nociception: the first one measures a spontaneous be-
havior, whereas the second measures a cutaneous hyper-
sensitivity to applied stimuli [57].
This is also consistent with our data on the prolonged
effect of multiple D-JNKI-1 treatment on autotomy be-
havior, which does not occur with single injection,
whereas both treatment protocols have the same results
on mechanical hyperalgesia. Autotomy behavior might
be elicited at higher levels as well: for example, it has
been shown that autotomy behavior correlates with the
expression of different dopamine receptors in the cingu-
late cortex [58].
Conclusions
Our study confirms a role for JNK signaling in regulat-
ing pain threshold, and underscores that the deletion of
all JNK isoforms can prevent the onset of neuropathic
pain. Moreover, the deletion of a single splice JNK iso-
form is sufficient to mitigate established sensory abnor-
malities. Our data suggest that drugs, which selectively
target individual Jnk gene products, can treat neuro-
pathic pain that specifically results from axonal sprout-
ing and pain transmission. Moreover, based on our
behavioral observations, pharmacological JNK inhibition
may offer a new option to prevent neuropathic pain
associated with surgery that involves nerve damage.
Methods
Experimental animals
JNK1-, JNK2-, and JNK3-null mice, created by gene tar-
geting [59-61] on the same C57BL/6, were kindly
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Pharmacology, Kiel, Germany) and were bred in our ani-
mal facility. Homozygotes and heterozygotes were distin-
guished from C57BL/6 wild-type mice by using a
polymerase chain reaction (PCR) assay. Animals were
housed under a 12h light/dark cycle and provided food
and water ad libitum. All experimental procedures on
live animals were performed under the supervision of a
licensed veterinarian, according to the European Com-
munities Council Directive of 24 November 1986 (86/
609/EEC) and University of Torino’s institutional guide-
lines on animal welfare (DL 116/92).
Surgical technique and drug administration
Adult (2–4 months-old) male mice with a KO of the
different JNK isoforms and age- matched wt mice,
underwent sciatic nerve transection. They were admi-
nistered isofluorane anesthesia plus O2 and N2O, the
right sciatic nerve was exposed below the tendon of
the obturator muscle. Without damaging the perineur-
ium, the nerve was tightly ligated with 6–0 silk thread
at two points separated by 4 mm and was transected
between these points. The nerve was gently mani-
pulated back into place and the incision closed with
4/0 suture.
To investigate whether JNK is involved in SNT-
induced CGRP and GAP43 expression, the peptide JNK
inhibitor D-JNKI-1 (0.3 mg/kg, 0.1 mM solution) was
injected i.p. in a separate group of wt animals, 30 min
before surgery. D-JNKI-1 was synthesized by linking the
10 amino acid human immunodeficiency virus Tat (48–
57) transporter sequence to a 20 amino acid JNK-
binding motif (JBD20) of JNK-interacting protein-1/islet-
brain 1 (JIP-1). The peptide was also synthesized as
protease-resistant D-form, to extend its half-life in vivo
[13]. The peptide inhibitor is highly selective and does
not affect the activity of 40 other protein kinases [13].
Based on previous reports of sciatic nerve lesions in
mice [23], we decided that 72h is a suitable time interval
for detecting axotomy-induced changes.
The number of mice/group was determined with a
standard power analysis [62]. We set the significance
level (probability of a type-I error) at 5% (α= 0.05) and
sought to choose a sample size that would minimize the
probability of type-II errors (β ≤ 10%). From our initial
experiment, we obtained estimates of the expected
effects of the 72h transection injury, and variability for a
given number of mice. On the basis of this analysis, we
determined that a sample size of four animals in each
treatment group would be sufficient to detect a 30% dif-
ference in the immunoreactivities (described below) with
a statistical power of 95%. In this paper, the injured and
uninjured hindpaws are referred to as ipsilateral and
contralateral hindpaws, respectively. Our controls werenaive mice. All efforts were made to minimize the num-
ber of animals used and their suffering.
Reverse transcription-PCR
Expression of Jnk1, Jnk2, Jnk3 and β-actin was analyzed
by reverse transcription (RT)-PCR.Total RNA was
extracted from DRGs with use of Trizol, according the
instructions of the supplier (Invitrogen, Milan, Italy).
Total RNA was treated with ribonuclease-free deoxy-
ribonuclease I for 15 minutes at room temperature. The
first- strand cDNA was synthesized with 5 μg of the total
RNA and 500 ng of random primers using the Super
Script first-strand synthesised system for reversetran-
scriptase–polymerase chain reaction (Invitrogen, Milan,
Italy). The following primers were used: 5′-AAACA
GGCCTAAATACGCTGGA-3′ and 5′-GACGGCTGC
CCTCTTATGAC-3′ for Jnk1; 5′-GAGCTGGTGAAA
GGTTGTGTGATATTCCA-3′ and 5′-AACAGTAATA
TACGGGTGGCGCAAG-3′ for JNK2; 5′-AACAATCG
CTACACCTCCAAAGAC-3′ and 5′-TGGCAATAGAT
GACACATCCAGG-3′ for JNK3. β-actin mRNA expres-
sion was used as an internal standard, and the primers
used for this were 5′- TCCATCATCATGAAGTGAC
GT-3′ and 5′-GAGCAATGATCTTGATCTTCAT-3′.
Western blots
Animals were rapidly killed and L3-L6 DRGs were
quickly removed and frozen in liquid nitrogen; they were
mechanically homogenized in a hypotonic buffer con-
taining a mixture of proteinase and phosphatise inhibi-
tors (Sigma-Aldrich, St. Louis, MO). Protein sample (30
μg) were separated on 12% SDS gel and transferred onto
PVDF membrane. The blots were blocked with 5% BSA
and incubated overnight at 4°C with the following anti-
bodies i) a polyclonal rabbit anti pJNK (1:500, Cell
Signaling Technology, Beverly, MA, Cat No. #9251,
lot.10). This antibody was produced by immunizing rab-
bits with a synthetic phospho-peptide corresponding to
residues surrounding Thr183/Tyr185 of human JNK.
pJNK was purified by protein A and peptide affinity
chromatography. It detects endogenous levels of p46
and p54 JNK dually phosphorylated at Thr183 and Tyr
185 [9]. ii) a polyclonal rabbit anti total JNK (1:500,Cell
Signaling Technology, Beverly, MA, Cat No. #9252,
lot.8). This antibody was produced by immunizing ani-
mals with a GST/human JNK2 fusion protein. The anti-
bodyis purified by protein A and peptide affinity
chromatography, and detects endogenous levels of p46
and p54 JNK [9]. Following incubation in primary
antibody, blots were further incubated with stabilized
HRP-conjugated goat anti-rabbit IgG (H+L) secondary
antibody (1:1000, Pierce, Rockford, USA, Cat No.
32460), and HRP activity was then detected with Super
Signal West Dura Extended Duration Substrate (Pierce,
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probed with monoclonal anti-acetylated tubulin antibody
Clone 6-11B-1 (1:10.000, Sigma, Missouri, USA, Cat
No. T6793).
Immunohistochemistry
After appropriate post-surgery survival times, animals
were killed with an overdose of anaesthetic (3% chloral
hydrate in saline) and perfused transcardially with 4%
paraformaldehyde in 0.1 M phosphate buffer (PB, pH
7.4). L4 DRGs were removed and postfixed in the same
fixative for two hours. The tissue was cryoprotected by
immersion over night in buffered 30% sucrose, embed-
ded, and frozen on cryostat medium (Bio-Optica, Milan,
Italy). DRG sections (10 μm) were serially cut in a cryo-
stat, mounted on TESPA (3-aminopropyl-trithoxysilan;
Fluka, St. Louis, MO, USA) coated slides and processed
for immunofluorescence staining.
Sections were incubated at 4°C overnight with i) a poly-
clonal rabbit anti GAP43 antibody (Abcam, Cambridge,
UK, Cat No. ab7462, lot.716099) diluted 1:250 in 1,5%
NDS PBS 0.3% Triton X-100. The antibody was obtained
by immunizing a rabbit with the Keyhole Limpet
haemocyanin-coupled synthetic peptide C- KEDPEAD-
QEHA, corresponding to amino acids 216–226 of rat
GAP43. On conventional Western blot analysis of cultured
cortical neurons, this antibody visualizes a single band at 43
kDa [63]. ii) A polyclonal rabbit antiserum to Calcitonin
Gene-Related Peptide (CGRP; Biomol, Plymouth, PA, USA,
Cat No. CA1134, lot. Z05177), diluted 1:500 in phosphate-
buffered saline (PBS) containing 5% normal donkey serum
(NDS; Sigma) and PBS 0.3% Triton X-100. This antibody
detects peptidergic nociceptive neurons, and was partially
purified by caprylic acid and ammonium sulphate precipita-
tion. Previous studies [64] show that CGRP (CA1134) pro-
duces a similar pattern of immunoreactivity in lumbar
DRGs after SNT.
After rinsing, primary antibodies were detected by in-
cubating sections for one hour at room temperature in
1:200 Cy3-coniugated donkey anti-rabbit IgG (H+L)
(Jackson Immuno Research Laboratories, West Grove,
PA, USA) or in 1:100 Cy2-coniugated donkey anti-rabbit
IgG (H+L) (Jackson Immuno Research Laboratories).
Sections were counterstained by incubation with DAPI
(4,6-Diamidino-2-phenyindole, dilactate; Sigma) diluted
1:10 in PBS 0.3% Triton X-100 for 10 minutes at room
temperature after immunohistochemical labelling. Con-
trols included sections treated with secondary antibody
alone, which did not show appreciable staining.
Quantitative morphometric analyses
Computer-assisted quantitative analyses of the CGRP
and GAP43 immunoreactivities was assessed at 20x with
a Nixon Eclipse 600 light microscope coupled with acomputer-assisted image analysis system (Neurolucida
software, Micro Bright Field, Williston, VT, USA). The
total number of positive neuron profiles was divided by
the total number of DAPI stained profiles in the L4
DRG sections, and the percentage of immunoreactive
neurons was calculated. Percentages obtained from 8–10
sections from each animal were averaged (at least three
animals for each neurochemical marker). Every section
was digitized, and images were acquired via red, green
and blue channels, with a 512x512 eight-bit matrix. Each
pixel was assigned a luminance value ranging from 0 to
255 in each channel. The lower threshold value was
determined from the unstained portions of the immu-
noreacted sections and from control sections,the upper
thresholdvalue was established from immunopositive
cells that highly express fluorochromeactivity. Only neu-
rons with visible nuclei and a brightness value of at least
20 (after subtraction of background staining) were
included in counts.
Behavioral testing
Animals were habituated to the testing environment
daily for one week before baseline testing. In all studies,
the observer was blind to the genotype of the mice, and
to the how each animal had been treated.
Walking tracks analysis
We used locomotor activity as an index of normal be-
havior. Mice were evaluated to obtain three footprint
parameters i) toe spread, or the distance between the
first and fifth toes; ii) print length, or the distance be-
tween the tip of the toe and the most posterior part of
the foot that was in contact with the ground; iii) stride
length. The assessments were carried out in two ways.
Animals were first placed on plexiglass corridor (60cm x
4.5 cm); a video camera was placed under the transpar-
ent corridor to record the walking tracks of each mouse.
The animal’s cage was placed at the end of the corridor
to induce the animal to walk to it. The hind feet of the
mice were dipped in ink and the animals were allowed
to walk along the corridor, which was lined with ordin-
ary white paper. For each animal, a mean of three foot-
prints was used in the assessment.
Rotarod test
Locomotor activity was also tested using arotarod appar-
atus (Model 760; UgoBasile, Comerio, Italy): mouse’s
ability to stay on a rotating rod that accelerated initially
from 4 rpm to a final speed of 32 rpm was assessed; the
cut-off time for the test was 300 sec. Mice were pre-
trained in the same rotarod apparatus at a constant
speed of 15 rpm once a day for 7 days before base-
line testing.
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The open field test was performed in a cube (50x50x50
cm) made of gray polyacrylic plastic plates; it had no ceil-
ing. Each mouse was transferred from its cage to a corner
of the arena, and its activity was recorded with a video
camera. The arena was cleaned with 70% ethanol and
water between trials. Horizontal activities were assessed
for 10 min, and analyzed using the EthoVision video
tracking system (Noldus). The center point of the body of
a freely moving mouse was captured to obtain the total
distance travelled in the arena, and quantitatively describe
the animal’s open field exploratory behavior.
Neuropathic pain test
Hyperalgesia induced by SNT was measured with use of
an automatic von Frey apparatus (Dynamic Plantar
Aesthesiometer, Model 37450, UgoBasile). On each test-
ing day, the nociceptive threshold of the hindpaws,
expressed as the force (in grams) at which the mouse
withdrew its paw in response to the mechanical stimu-
lus, was recorded. For habituation, mice were placed in
plastic cages with a wire net floor, 5 min before the ex-
periment. The mechanical stimulus was applied to the
mid-plantar surface of the hindpaw to induce a slight
pressure to the skin, as described [65,66]. Ipsilateral and
contralateral withdrawal thresholds were taken as the
mean of three consecutive measurements per paw, with
a 10 s interval between each measurement.
A cut-off force of 20 grams was used, one we had
ascertained that no injury was produced within this
force range. Mice were tested from day 2 pre-injury to
day 30 post-injury.
Autotomy score
Autotomy was assessed at all time-points after surgery, with
use of the scale described by Wiesenfeld and Hallin [67].
Scoring points ranged from 0 to 5, where 0=normal
undamaged hindpaw; 1= the tips of one or more nails were
removed; 2=one or more nails totally removed and dam-
age to the distal portion of one or more digits; 3 =one or
more digits totally removed; and 4=one or more digits to-
tally removed plus damage to the foot. No animals scored
higher than 4.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
version 4.0 (GraphPad software, San Diego, CA). All
values were presented as mean+ standard error of the
mean (SEM). Means were compared by one way analysis
of variance (ANOVA) and Student’s t-test with Bonferroni
as a post-hoc test. Behavioral data related to hyperalgesia
were analyzed using two-way ANOVA of repeated mea-
sures, followed by a Tukey–Kramer post-hoc comparison.
Differences were considered significant at p< 0.05 level.Additional files
Additional file 1: Walking track analysis of JNK KO mice. Locomotor
activity of JNK KOs was similar to the wt mice as measured by comparing
the stride length of all tested animals. Data are presented as mean + SEM.
p = 0.92 by one-way ANOVA; n = 48.
Additional file 2: Open field behavior of JNK KO mice. Mice were
placed in an open field box and movements and behaviors were
recorded for 10 min using a video camera in the vertical plane. There
were no differences between JNK KO and wt mice in the total distance
travelled in the arena. Data are presented as mean + SEM. P = 0.91 by
one-way ANOVA; n = 48.
Abbreviations
PK: Protein Kinase; MAPKs: Mitogen-Activated Protein Kinases;
ERK: Extracellular Signal-Regulated Kinase; JNK: c-Jun N-terminal Kinase;
DRGs: Dorsal Root Ganglia; D-JNKI-1: D-form of the JNK binding domain of
JNK-Interacting protein-1; STF: Activating Transcription Factor; Elk-1:
EtsLiKe gene-1; SNT: Sciatic Nerve Transection; AP-1: Activator protein 1;
GAP-43: Growth Associated Protein; KO: Calcitonin Gene Related Peptide;
NGF: Neuronal Growth Factor; dpo: Days Post Operation; KO: KnockOut;
wt: wild-type; RT-PCR: Reverse Transcription; p: phosphorylated;
Thr: Threonine; Tyr: Tyrosone; IR: ImmunoReactive; SNL: Spinal Nerve Ligation;
MAP: Microtubules Associated Protein; CD: cluster of differentiation.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
GM designed, performed the experiments and wrote the manuscript
together with AV. IR performed part of the experiments. SC contributed to
behavioral tests and statistical analysis. VV contributed to the RT-PCR. CB
contributed to design of experimentation and of drug administration. AV
and FR supervised the experiments. All authors read and approved the final
manuscript.
Acknowledgements
Supported by FAIP (Federazione Associazioni Italiane Paratetraplegici),
Fondazione Cassa di Risparmio di Cuneo, MIUR (PRIN) and EEC
(Stressprotect) grants to AV. In partial fulfilment of the requirements for the
achievement of the Doctorate degree by GM.
Author details
1Department of Neuroscience, Neuroscience Institute of Turin (NIT),
University of Turin, I-10125, Turin, Italy. 2Neuroscience Institute of the
Cavalieri-Ottolenghi Foundation (NICO), University of Turin, Regione Gonzole
10, 10043, Orbassano Turin, Italy. 3Group of Neuroplasticity and Regeneration,
Institute of Neuroscience-CIBERNED, Universitat Autonoma de Barcelona,
E-08193, Bellaterra, Barcelona, Spain. 4Division of Medical Genetics,
CHUV-University Hospital, 1011, Lausanne, Switzerland.
Received: 7 February 2012 Accepted: 22 May 2012
Published: 22 May 2012
References
1. Jensen TS, Gottrup H, Sindrup SH, Bach FW: The clinical picture of
neuropathic pain. Eur J Pharmacol 2001, 429:1–11.
2. Hucho T, Levine JD: Signaling pathways in sensitization: toward a
nociceptor cell biology. Neuron 2007, 55:365–376.
3. Costigan M, Scholz J, Woolf CJ: Neuropathic pain: a maladaptive
response of the nervous system to damage. Annu Rev Neurosci 2009,
32:1–32.
4. Devor M: Neuropathic pain: what we do with all these theories? Acta
Anaesthesiol Scand 2001, 45:1121–1127.
5. Ghosh A, Greenberg ME: Calcium signaling in neurons: molecular
mechanisms and cellular consequences. Science 1995, 268:239–247.
6. Matzner O, Devor M: Hyperexcitability at sites of nerve injury depends on
voltage-sensitive Na + channels. J Neurophysiol 1994, 72:349–359.
7. Obata K, Yamanaka H, Dai Y, Tachibana T, Fukuoka T, Tokunaga A,
Yoshikawa H, Noguchi K: Differential activation of extracellular
Manassero et al. Molecular Pain 2012, 8:39 Page 15 of 16
http://www.molecularpain.com/content/8/1/39signal- regulated protein kinase in primary afferent neurons regulates
brain- derived neurotrophic factor expression after peripheral
inflammation and nerve injuty. J Neurosci 2003, 23:4117–4126.
8. Jin SX, Zhuang ZY, Woolf CJ, JI RR: p38 mitogen-activated protein kinase
is activated after a spinal nerve ligation in spinal cord microglia and
dorsal root ganglion neurons and contributes to the generation of
neuropathic pain. J Neurosci 2003, 23:4017–4022.
9. Zhuang ZY, Wen YR, Zhang DR, Borsello T, Bonny C, Strichartz GR,
Decosterd I, Ji RR: A Peptide c-Jun N-Terminal Kinase (JNK) Inhibitor
blocks mechanical allodynia after spinal nerve ligation: respective roles
of JNK Activation in primary sensory neurons and spinal astrocytes for
neuropathic pain development and maintanance. J Neurosci 2006,
26:3551–3560.
10. Kenney AM, Kocsis JD: Peripheral axotomy induces long-term c-Jun
amino-terminal kinase-1 activation and activator protein-1 binding
activity by c-Jun and junD in adult rat dorsal root ganglia in vivo.
J Neurosci 1998, 18:1318–1328.
11. Herdegen T, Waetzig V: The JNK and p38 signal transduction following
axotomy. Restor Neurol Neurosci 2001, 19:29–39.
12. Borsello T, Bonny C: Use of cell-permeable peptides to prevent neuronal
degeneration. Trends Mol Med 2004, 10:239–244.
13. Borsello T, Clarke PG, Vercelli A, Repici M, Schorderet DF, Bogousslavsky J,
Bonny C: A peptide inhibitor of c-Jun N-terminal kinase protects against
excitotoxicity and cerebral ischemia. Nat Med 2003, 9:1180–1186.
14. Repici M, Centeno C, Tomasi S, Forloni G, Bonny C, Vercelli A, Borsello T:
Time-course of c-Jun N-terminal kinase activation after cerebral ischemia
and effect of D-JNKI-1 on c-Jun and caspase-3 activation. Neuroscience
2007, 150:40–49.
15. Gao YJ, Cheng JK, Zeng Q, Xu ZZ, Decosterd I, Xu X, Ji RR: Selective
inhibition of JNK with a peptide inhibitor attenuates pain
hypersensitivity and tumorgrowyh in a mouse skin cancer pain. Exp
Neurol 2009, 219:146–155.
16. Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Derijard B, Davis RJ:
Selective interaction of JNK protein kinase isoforms with transcription
factors. EMBO J 1996, 15:2760–2770.
17. Davis RJ: Signal transduction by the JNK group of MAP kinases. Cell 2000,
103:239–252.
18. Martin JH, Mohit AA, Miller CA: Developmental expression in the mouse
nervous system the p493F12 SAP kinase. Brain Res Mol Brain Res 1996,
35:47–57.
19. Raivich G, Behrens A: Role of the AP-1 transcription factor c-Jun in
developing, adult and injured brain. Prog Neurobiol 2006, 78:347–363.
20. Mogil JS, Miermeister F, Seifert F, Strasburg K, Zimmermann K, Reinold H,
Austin JS, Bernardini N, Chesler EJ, Hofmann HA, Hordo C, Messlinger K,
Nemmani KV, Rankin AL, Ritchie J, Siegling A, Smith SB, Sotocinal S, Vater A,
Lehto SG, Klussman S, Quirion R, Michaelis M, Devor M, Reeh PW: Variable
sensitivity to noxious heat is mediated by differential expression of the
CGRP gene. Proc Natl Acad Sci USA 2005, 102:12938–12943.
21. Hoffman PN: Expression of GAP43, a rapidly transported growth-
associated protein, and class II beta tubulin, a slowly transported
cytoskeletal protein, are coordinated in regenerating neurons. J Neurosci
1989, 9:893–897.
22. Eggen BJL, Nielander HB, Rensen-de Leeuw MGA, Schotman P, Gispen WH,
Schrama LH: Identification of two promoter regions in the rat B-50
/GAP43 gene. Mol Brain Res 1994, 23:221–234.
23. Zheng LF, Wang R, Xu YZ, Yi XN, Zhang WJ, Zeng ZC: Calcitonin gene-
related peptide dynamics in rat dorsal root ganglia and spinal
cord following different sciatic nerve injuries. Brain Res 2008,
1187:20–32.
24. Doya H, Ohtori S, Fujitani M, Saito T, Hata K, Ino H, Takahashi K, Moriya H,
Yamashita T: c-Jun N-terminal kinase activation in dorsal root ganglion
contributes to pain hypersensitivity. Biochem Biophys Res Commun 2005,
335:132–138.
25. Benowitz LI, Routtenberg A: GAP-43: an intrinsic determinant of neuronal
development and plasticity. Trends Neurosci 1997, 20:84–91.
26. Rossi F, Gianola S, Corvetti L: Regulation of intrinsic neuronal properties
for axon growth and regeneration. Prog Neurobiol 2007, 81:1–28.
27. Gao YJ, Zhang L, Samad OA, Suter MR, Yasuhiko K, Xu ZZ, Park JY, Lind AL,
Ma Q, Ji RR: JNK-induced MCP-1 production in spinal cord astrocytes
contributes to central sensitization and neuropathic pain. J Neurosci 2009,
29:4096–4108.28. Persson AK, Thun J, Xu XJ, Wiesenfeld-Hallin Z, Ström M, Devor M, Lidman
O, Fried K: Autotomy behaviour correlates with the DRG and spinal
expression of sodium channels in inbred mouse strains. Brain Res 2009,
1285:1–13.
29. Mailis A: Compulsive targeted self-injurious behaviour in humans with
neuropathic pain: a counterpart of animal autotomy? Four case reports
and literature review. Pain 1996, 64:569–578.
30. Le Bars D, Gozariu M, Cadden SW: Animal models of nociception.
Pharmacol Rev 2001, 53:597–652.
31. Wall PD, Devor M, Inbal R, Scadding JW, Schonfeld D, Seltzer Z, Tomkiewicz
MM: Autotomy following peripheral nerve lesions: experimental
anaesthesia dolorosa. Pain 1979, 7:103–111.
32. Sandkühler J: Models and mechanisms of hyperalgesia and allodynia.
Physiol Rev 2009, 89:707–758.
33. Lindwall C, Kanje M: Retrograde axonal transport of JNK signalling
molecules influence injury induced nuclear changes in p-c-JUN and
ATF3 in adult rat sensory neurones. Mol Cell Neurosci 2005, 29:269–282.
34. Lindwall C, Dahlin L, Lundborg G, Kanje M: Inhibition of c-Jun
phosphorylation redces axonal outgrowth of adult rat nodose ganglia
and dorsal root ganglia sensory neurons. Mol Cell Neurosci 2004, 27:
267–279.
35. Lindwall C, Kanje M: The Janus role of c-Jun: Cell death versus survival
and regeneration of neonatal sympathrtic and sensory neurons. Exp
Neurol 2005, 196:184–19436.
36. Horiuchi D, Collins CA, Bhat P, Barkus RV, Diantonio A, Saxton WM: Control
of a kinesin-cargo linkage mechanism by JNK pathway kinases. Curr Biol
2007, 17:1313–1317.
37. Cavalli V, Kujala P, Klumperman J, Goldstein LSB: Sunday Driver links axonal
transport to damage signaling. J Cell Biol 2005, 28:775–787.
38. Dajas-Bailador F, Jones EV, Whitmarsh AJ: The JIP1 Scaffold protein
regulates axonal development in cortical neurones. Curr Biol 2008,
18:221–226.
39. Chang L, Jones Y, Ellisman MH, Goldstein LSB, Karin M: JNK1 is required for
maintenance of neuronal microtubule-associated proteins. Developmental
Cell 2003, 4:521–533.
40. Bouquet C, Soares S, Von Boxberg Y, Ravaille-Veron M, Propst F, Nothias F:
Microtubule-associated protein 1B controls directionality of growth cone
migration and axonal branching in regeneration of adult dorsal root
ganglia neurons. J Neurosci 2004, 24:7204–7213.
41. Soares S, Barnat M, Salim C, Von Boxberg Y, Ravaille-Veron M, Nothias F:
Extensive structural remodeling of the injured spinal cord revealed by
phosphorylated MAP1B in sprouting axons and degenerating neurons.
Eur J Neurosci 2007, 26:1446–1461.
42. Waetzig V, Katja L, Haeusgen W, Herdegen T: c-Jun N-terminal kinases
mediate Fas-induced neurite regeneration in PC12 cell. Biochem
Phamacology 2008, 76:1476–1484.
43. Lee SE, Kim JH: Involvement of substance P and calcitonin gene-related
peptide in development and maintenance of neuropathic pain from
spinal nerve injury model of rat. Neurosci Res 2007, 58:245–249.
44. Hökfelt T, Zhang X, Wiesenfeld HZ: Messanger plasticity in primary
sensory neurons following axotomy and its functional implications.
Trends Neurosci 1994, 17:22–30.
45. Todd AJ: Neuronal circuitry for pain processing in the dorsal horn. Nat
Rev Neurosci 2010, 12:823–836.
46. Scholz J, Woolf CJ: The neuropathic pain triad: neurons, immune cell and
glia. Nat Neurosci 2007, 10:361–368.
47. Gao YJ, Zhang L, Ji RR: Spinal injection of TNF-α-activated astrocytes
produces persistent pain symptom mechanical allodynia by releasing
monocyte chemoattractant protein-1. Glia 2010, 58:1871–1880.
48. Cirillo G, Cavaliere C, Bianco MR, De Simone A, Colangelo AM, Sellitti S,
Alberghina L, Papa M: Intrathecal NGF administration reduces reactive
astrocytosis and changes neurotrophin receptors expression pattern in a
rat model of neuropathic pain. Cell Mol Neurobiol 2010, 30:51–62.
49. Mogil JS, Yu L, Basbaum AI: Pain genes?: natural variation and transgenic
mutants. Annu Rev Neurosci 2000, 23:777–811.
50. Kristiansen KA, Edvinsson L: Neurogenic inflammation: a study of rat
trigeminal ganglion. J Headache Pain 2010, In press.
51. Liu MG, Zhang FK, Guo SW, Zhao LF, An YY, Cui XY, Chen J:
Phosphorylation of c-Jun N-terminal kinase isoforms and their different
roles in spinal cord dorsal horn and primary somatosensory cortex.
Neurosci Lett 2007, 427:39–43.
Manassero et al. Molecular Pain 2012, 8:39 Page 16 of 16
http://www.molecularpain.com/content/8/1/3952. Toyoda H, Zhao MG, Xu H, Wu LJ, Ren M, Zhuo M: Requirement of
extracellular signal-regulated kinase/mitogen-activated protein kinase
for long-term potentiation in adult mouse anterior cingulate cortex. Mol
Pain 2007, 3:36.
53. Liu MG, Wang RR, Chen XF, Zhang FK, Cui XY, Chen J: Differential roles of
ERK, JNK and p38 MAPK in pain-related spatial and temporal
enhancement of synaptic responses in the hippocampal formation of
rats:multi-electrode array recordings. Brain Res 2011, 1382:57–69.
54. Sherrin T, Blank T, Hippel C, Rayner M, Davis RJ, Todorovic C: Hippocampal
c-Jun-N-terminal kinases serve as negative regulators of associative
learning. J Neurosci 2010, 30:13348–61.
55. Norcini M, Vivoli E, Galeotti N, Bianchi E, Bartolini A, Ghelardini C:
Supraspinal role of protein kinase C in oxaliplatin-induced neuropathy in
rat. Pain 2009, 146:141–147.
56. Mogil JS, Wilson SG, Bon K, Lee SE, Chung K, Raber P, Pieper JO, Hain HS,
Belknap JK, Hubert L, Elmer GI, Chung JM, Devor M: Heritability of
nociception I:responses of 11 inbred mouse strains on 12 measures of
nociception. Pain 1999, 80:67–82.
57. Mogil JS, Wilson SG, Bon K, Lee SE, Chung K, Raber P, Pieper JO, Hain HS,
Belknap JK, Hubert L, Elmer GI, Chung JM, Devor M: Heritability of
nociception II. ‘Types’ of nociception revealed by genetic correlation
analysis. Pain 1999, 80:83–93.
58. Ortega-Legaspi JM, de Gortari P, Garduño-Gutiérrez R, Amaya MI, León-Olea
M, Coffeen U, Pellicer F: Expression of the dopaminergic D1 and D2
receptors in the anterior cingulated cortex in a model of neuropathic
pain. Mol Pain 2011, 7:97.
59. Dong C, Yang DD, Wysk M, Whitmarsh AJ, Davis RJ, Flavell RA: Defective T
Cell Differentiation in the Absence of Jnk1. Science 1998, 282:2092–2095.
60. Yang DD, Conze D, Whitmarsh AJ, Barret T, Davis RJ, Rincón M, Flavell RA:
Differentiation of CD4+ T Cells to Th1 Cells Requires MAP Kinase JNK2.
Immunity 1998, 9:575–585.
61. Yang DD, Kuan CY, Whitmarsh AJ, Rincón M, Zheng TS, Davis RJ, Rakic P,
Flavell RA: Absence of excitotoxicity-induced apoptosis in the
hippocampus of mice lacking the Jnk3 gene. Nature 1997, 389:865–870.
62. Faul F, Erdfelder E, Lang AG, Buchner A: G*Power3: A flexible statistical
power analysis program for the social, behavioral, and biomedical
sciences. Behav Res Methods 2007, 39:175–191.
63. Herrero-Mendez A, Almeida A, Fernandez E, Maestre C, Moncada S, Bolanos
J: The bioenergetic and antioxidant status of neurons is controller by
continuous degradation of a key glicoli enzyme by APC/C-Cdh1. Nature
Cell Biology 2009, 11:747–752.
64. Gushchina S, Leinster V, Wu D, Jasim A, Demestre M, de HerediaL Lopez,
Michael GJ, Barker PA, Richardson PM, Magoulas C: Observations on the
function of nuclear factor kappa B (NF-κB) in the survival of adult
primary sensory neurons after nerve injury. Mol Cellular Neurosci 2009,
40:207–216.
65. Luvisetto S, Marinelli S, Cobianchi S, Pavone F: Anti-allodynic efficacy of
botulinum neurotoxin A in a model of neuropathic pain. Neuroscience
2007, 145:1–4.
66. Cobianchi S, Marinelli S, Florenzano F, Pavone F, Luvisetto S: Short- but not
long-lasting treadmill running reduces allodynia and improves
functional recovery after peripheral nerve injury. Neuroscience 2010,
168:273–287.
67. Wiesenfeld Z, Hallin RG: Influence of nerve lesions, strain differences and
continuous cold stress on chronic pain behavior in rats. Physiol Behav
1981, 27:735–740.
doi:10.1186/1744-8069-8-39
Cite this article as: Manassero et al.: Role of JNK isoforms in the
development of neuropathic pain following sciatic nerve transection in
the mouse. Molecular Pain 2012 8:39.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
